Content deleted Content added
added missing identifiers to infobox |
Graeme Bartlett (talk | contribs) added Category:Pyrrolidines using HotCat |
||
(3 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Drug for the treatment of hepatitis C}} |
{{Short description|Drug for the treatment of hepatitis C}} |
||
{{cs1 config|name-list-style=vanc|display-authors=6}} |
|||
{{Infobox drug |
{{Infobox drug |
||
| drug_name = Coblopasvir |
| drug_name = Coblopasvir |
||
Line 68: | Line 69: | ||
}} |
}} |
||
'''Coblopasvir''' is a pharmaceutical drug for the treatment of [[hepatitis C]].<ref>{{cite journal | |
'''Coblopasvir''' is a pharmaceutical drug for the treatment of [[hepatitis C]].<ref>{{cite journal | vauthors = Rao H, Song G, Li G, Yang Y, Wu X, Guan Y, Mao Q, Jiang X, Wang C, Zhang Y, Jia J, Guo X, Li C, Ning J, Qin H, Pan H, Wei L | title = Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis | journal = Journal of Viral Hepatitis | volume = 27 | issue = 1 | pages = 45–51 | date = January 2020 | pmid = 31520460 | doi = 10.1111/jvh.13208 }}</ref> It is a pan-genotypic inhibitor of HCV [[NS5A|nonstructural protein 5A]].<ref name = "Gao_2020" /> |
||
In China, it is approved for use in combination with [[sofosbuvir]] for treating naïve or [[interferon]]‐experienced adults chronically monoinfected patients with [[Hepatitis C virus|HCV]] of genotype 1, 2, 3 and 6, with or without compensated cirrhosis.<ref>{{cite journal | |
In China, it is approved for use in combination with [[sofosbuvir]] for treating naïve or [[interferon]]‐experienced adults chronically monoinfected patients with [[Hepatitis C virus|HCV]] of genotype 1, 2, 3 and 6, with or without compensated cirrhosis.<ref name = "Gao_2020">{{cite journal | vauthors = Gao Y, Kong F, Li G, Li C, Zheng S, Lin J, Wen X, Hu J, Wang X, Wu X, Xing H, Jia J, Jia Z, Guan Y, Li C, Wu G, Gao Z, Mou Z, Ning Q, Mao Q, Yang Y, Ning J, Li L, Pan H, Zhou D, Ding Y, Qin H, Niu J | title = Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial | journal = Liver International | volume = 40 | issue = 11 | pages = 2685–2693 | date = November 2020 | pmid = 33047868 | pmc = 7702130 | doi = 10.1111/liv.14633 }}</ref> |
||
==References== |
== References == |
||
{{reflist}} |
{{reflist}} |
||
Line 82: | Line 83: | ||
[[Category:Methyl esters]] |
[[Category:Methyl esters]] |
||
[[Category:Carbamates]] |
[[Category:Carbamates]] |
||
[[Category:Isopropyl compounds]] |
|||
[[Category:Pyrrolidines]] |
|||
{{antiinfective-drug-stub}} |
{{antiinfective-drug-stub}} |
Latest revision as of 08:10, 11 May 2024
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C41H50N8O8 |
Molar mass | 782.899 g·mol−1 |
|
Coblopasvir is a pharmaceutical drug for the treatment of hepatitis C.[1] It is a pan-genotypic inhibitor of HCV nonstructural protein 5A.[2]
In China, it is approved for use in combination with sofosbuvir for treating naïve or interferon‐experienced adults chronically monoinfected patients with HCV of genotype 1, 2, 3 and 6, with or without compensated cirrhosis.[2]
References[edit]
- ^ Rao H, Song G, Li G, Yang Y, Wu X, Guan Y, et al. (January 2020). "Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis". Journal of Viral Hepatitis. 27 (1): 45–51. doi:10.1111/jvh.13208. PMID 31520460.
- ^ a b Gao Y, Kong F, Li G, Li C, Zheng S, Lin J, et al. (November 2020). "Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial". Liver International. 40 (11): 2685–2693. doi:10.1111/liv.14633. PMC 7702130. PMID 33047868.